Mass spectrometry imaging for early discovery and development of cancer drugs

A drug delivery system (DDS) is a method for delivering a drug to its site of action in the body, with the goal of achieving therapeutic benefits while reducing adverse effects. Pharmacokinetics (PK) and pharmacodynamics (PD) studies have been conducted to evaluate drug delivery, but these approache...

Full description

Bibliographic Details
Main Authors: Masahiro Yasunaga, Shino Manabe, Masaru Furuta, Koretsugu Ogata, Yoshikatsu Koga, Hiroki Takashima, Toshirou Nishida, Yasuhiro Matsumura
Format: Article
Language:English
Published: American Institute of Mathematical Sciences 2018-04-01
Series:AIMS Medical Science
Subjects:
Online Access:http://www.aimspress.com/medicalScience/article/1934/fulltext.html
id doaj-5244f51824724ef8893a87432f9d043a
record_format Article
spelling doaj-5244f51824724ef8893a87432f9d043a2020-11-25T02:00:19ZengAmerican Institute of Mathematical SciencesAIMS Medical Science2375-15762018-04-015216218010.3934/medsci.2018.2.162medsci-05-02-162Mass spectrometry imaging for early discovery and development of cancer drugsMasahiro Yasunaga0Shino Manabe1Masaru Furuta2Koretsugu Ogata3Yoshikatsu Koga4Hiroki Takashima5Toshirou Nishida6Yasuhiro Matsumura7Division of Developmental Therapeutics, EPOC, National Cancer Center (6-5-1 Kashiwanoha, Kashiwa-shi, Chiba 277-8577, Japan), JapanSynthetic Cellular Chemistry Laboratory, RIKEN (Hirosawa, Wako, Saitama 351-0198, Japan), JapanbrShimadzu Corporation (1, Nishinokyo-Kuwabaracho, Nakagyo-ku, Kyoto 604-8511, Japan), JapanbrShimadzu Corporation (1, Nishinokyo-Kuwabaracho, Nakagyo-ku, Kyoto 604-8511, Japan), JapanbrDivision of Developmental Therapeutics, EPOC, National Cancer Center (6-5-1 Kashiwanoha, Kashiwa-shi, Chiba 277-8577, Japan), JapanDivision of Developmental Therapeutics, EPOC, National Cancer Center (6-5-1 Kashiwanoha, Kashiwa-shi, Chiba 277-8577, Japan), JapanNational Cancer Center Hospital (5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan), JapanDivision of Developmental Therapeutics, EPOC, National Cancer Center (6-5-1 Kashiwanoha, Kashiwa-shi, Chiba 277-8577, Japan), JapanA drug delivery system (DDS) is a method for delivering a drug to its site of action in the body, with the goal of achieving therapeutic benefits while reducing adverse effects. Pharmacokinetics (PK) and pharmacodynamics (PD) studies have been conducted to evaluate drug delivery, but these approaches are rarely used in the early stages of drug discovery and development. We demonstrated that the tumor stromal barrier inhibits drug distribution within tumor tissue, especially in refractory cancers such as pancreatic cancer. This poses an obstacle to the discovery of new drugs, and is difficult to overcome using conventional <em>in vitro</em> drug discovery methods. In addition, we are also developing new DDS drugs and antibody-drug conjugates (ADCs). These agents act via four steps: Systemic circulation, the enhanced permeability and retention (EPR) effect, penetration within the tumor tissue, and action on cells including controlled drug release. Most of these activities can be evaluated by conventional biological or pharmacological assays. However, it is difficult to examine drug distribution and controlled drug release within targeted tissues. Recent advances in mass spectrometry imaging (MSI) allow examining drug delivery much more conveniently with the off-labeling. A mass microscope, a new type of matrix-associated laser desorption/ionization (MALDI)-MSI analyzer, is a microscope coupled with an atmospheric MALDI and quadruple ion trap time-of-flight (TOF) mass spectrometer, and can provide imaging data with enhanced resolution and high sensitivity. Using a mass microscope, we succeeded in visualizing the EPR effect of a polymeric micelle drug and controlled drug release by an ADC. Currently, we are developing a new drug imaging method using electrospray ionization (ESI)-MSI. Here, we review the use of MSI in early stages of drug discovery and development, as well as our related recent work.http://www.aimspress.com/medicalScience/article/1934/fulltext.htmldrug discovery and developmentmolecular imagingmass spectrometry imaging (MSI)drug delivery system (DDS)antibody-drug conjugate (ADC)MALDI (matrix-associated laser desorption/ionization)electrospray ionization (ESI)mass microscope
collection DOAJ
language English
format Article
sources DOAJ
author Masahiro Yasunaga
Shino Manabe
Masaru Furuta
Koretsugu Ogata
Yoshikatsu Koga
Hiroki Takashima
Toshirou Nishida
Yasuhiro Matsumura
spellingShingle Masahiro Yasunaga
Shino Manabe
Masaru Furuta
Koretsugu Ogata
Yoshikatsu Koga
Hiroki Takashima
Toshirou Nishida
Yasuhiro Matsumura
Mass spectrometry imaging for early discovery and development of cancer drugs
AIMS Medical Science
drug discovery and development
molecular imaging
mass spectrometry imaging (MSI)
drug delivery system (DDS)
antibody-drug conjugate (ADC)
MALDI (matrix-associated laser desorption/ionization)
electrospray ionization (ESI)
mass microscope
author_facet Masahiro Yasunaga
Shino Manabe
Masaru Furuta
Koretsugu Ogata
Yoshikatsu Koga
Hiroki Takashima
Toshirou Nishida
Yasuhiro Matsumura
author_sort Masahiro Yasunaga
title Mass spectrometry imaging for early discovery and development of cancer drugs
title_short Mass spectrometry imaging for early discovery and development of cancer drugs
title_full Mass spectrometry imaging for early discovery and development of cancer drugs
title_fullStr Mass spectrometry imaging for early discovery and development of cancer drugs
title_full_unstemmed Mass spectrometry imaging for early discovery and development of cancer drugs
title_sort mass spectrometry imaging for early discovery and development of cancer drugs
publisher American Institute of Mathematical Sciences
series AIMS Medical Science
issn 2375-1576
publishDate 2018-04-01
description A drug delivery system (DDS) is a method for delivering a drug to its site of action in the body, with the goal of achieving therapeutic benefits while reducing adverse effects. Pharmacokinetics (PK) and pharmacodynamics (PD) studies have been conducted to evaluate drug delivery, but these approaches are rarely used in the early stages of drug discovery and development. We demonstrated that the tumor stromal barrier inhibits drug distribution within tumor tissue, especially in refractory cancers such as pancreatic cancer. This poses an obstacle to the discovery of new drugs, and is difficult to overcome using conventional <em>in vitro</em> drug discovery methods. In addition, we are also developing new DDS drugs and antibody-drug conjugates (ADCs). These agents act via four steps: Systemic circulation, the enhanced permeability and retention (EPR) effect, penetration within the tumor tissue, and action on cells including controlled drug release. Most of these activities can be evaluated by conventional biological or pharmacological assays. However, it is difficult to examine drug distribution and controlled drug release within targeted tissues. Recent advances in mass spectrometry imaging (MSI) allow examining drug delivery much more conveniently with the off-labeling. A mass microscope, a new type of matrix-associated laser desorption/ionization (MALDI)-MSI analyzer, is a microscope coupled with an atmospheric MALDI and quadruple ion trap time-of-flight (TOF) mass spectrometer, and can provide imaging data with enhanced resolution and high sensitivity. Using a mass microscope, we succeeded in visualizing the EPR effect of a polymeric micelle drug and controlled drug release by an ADC. Currently, we are developing a new drug imaging method using electrospray ionization (ESI)-MSI. Here, we review the use of MSI in early stages of drug discovery and development, as well as our related recent work.
topic drug discovery and development
molecular imaging
mass spectrometry imaging (MSI)
drug delivery system (DDS)
antibody-drug conjugate (ADC)
MALDI (matrix-associated laser desorption/ionization)
electrospray ionization (ESI)
mass microscope
url http://www.aimspress.com/medicalScience/article/1934/fulltext.html
work_keys_str_mv AT masahiroyasunaga massspectrometryimagingforearlydiscoveryanddevelopmentofcancerdrugs
AT shinomanabe massspectrometryimagingforearlydiscoveryanddevelopmentofcancerdrugs
AT masarufuruta massspectrometryimagingforearlydiscoveryanddevelopmentofcancerdrugs
AT koretsuguogata massspectrometryimagingforearlydiscoveryanddevelopmentofcancerdrugs
AT yoshikatsukoga massspectrometryimagingforearlydiscoveryanddevelopmentofcancerdrugs
AT hirokitakashima massspectrometryimagingforearlydiscoveryanddevelopmentofcancerdrugs
AT toshirounishida massspectrometryimagingforearlydiscoveryanddevelopmentofcancerdrugs
AT yasuhiromatsumura massspectrometryimagingforearlydiscoveryanddevelopmentofcancerdrugs
_version_ 1724961392407085056